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Introduction 
 
14-3-3 proteins are a family of conserved acidic 
proteins of which there are seven different iso-
forms found in mammals (ζ, γ, η, ε, β, θ, σ) [1]. 
They function as molecular adapters which in-
teract with key signaling molecules and thereby 
regulate various cell functions including me-
tabolism, division, differentiation, autophagy 
and apoptosis [2-4]. 14-3-3 proteins are ubiqui-
tously expressed, but are most abundant in the 
brain [5]. They are generally considered to be 
cytosolic proteins, although subcellular frac-
tionation analyses of rat brain has shown they 
are also present in other compartments, includ-
ing intracellular organelles such as mitochon-
dria and the endoplasmic reticulum [6-8]. 
Knockout of 14-3-3 isoforms has demonstrated 
essential roles for some while loss of others 
appears to be adequately compensated by the 
remaining isoforms [9].  
 
14-3-3 proteins have three main modes of ac-
tion; altering conformation of their targets, 
physically occluding structural features, and 
scaffolding [9]. By doing so, 14-3-3 proteins 
influence the functions of their targets, includ-
ing modulating intracellular trafficking, blocking 
or activating enzymatic activity and influencing 
posttranslational modification. The identifica-
tion of two binding motifs (RSXpSXP and RXY/
FXpSP, where p denotes a phosphorylated ser-
ine and X denotes any amino acid) [10] pro-
vided critical insight into the mechanism of their 
binding, although many target proteins do not 
contain these motifs [9]. The advent of proteo-
mic profiling has facilitated a large increase in 
the identification of 14-3-3 target proteins and 
to date over 200 different binding partners have 
been identified [11-15]. These include protein 
kinases, phosphatases, signaling molecules, 
adaptors/scaffolding, transcription factors, re-
ceptors and cytoskeletal proteins.  
 
Aberrant expression or function of 14-3-3 pro-
teins has been linked to several diseases in-
cluding cancer [16] and neurodegeneration [5]. 
Particular interest has emerged on 14-3-3ζ 
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(Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta poly-
peptide). Subcellular fractionation of human 
hippocampus showed the ζ isoform to be par-
ticularly abundant, and one of a sub-set of iso-
forms present in the microsome-enriched frac-
tion containing the endoplasmic reticulum and 
Golgi apparatus [7]. Altered expression of 14-3-
3ζ has been reported in Alzheimer’s disease 
[17], spinocerebellar ataxia [18], autism spec-
trum and neuropsychiatric disorders [19]. Lev-
els of 14-3-3ζ were also found to be elevated in 
the microsomal fraction of the hippocampus 
from patients with temporal lobe epilepsy [7], 
and other data has emerged to suggest seizures 
alter the expression or function of 14-3-3ζ [7, 
20, 21]. The presence of 14-3-3ζ in cerebrospi-
nal fluid may also be a biomarker of seizure-
induced brain injury [22]. 
 
The 14-3-3ζ brain interactome has not been 
characterized. Several studies have character-
ized 14-3-3 interactomes, although the degree 
of overlap between studies has been quite low 
because of the various isoforms, models and 
platforms employed [9]. Approaches used in-
clude yeast two-hybrid screening [23], protein 
microarrays [15], and using tagged 14-3-3 to 
purify bound proteins [13]. Here we used a re-
combinant His-tagged 14-3-3ζ to elute interact-
ing proteins from mouse brain combined with 
tandem mass spectrometric (MS/MS) identifica-
tion.  
 
Methods 
 
His-tagged 14-3-3 zeta 
 
To identify novel 14-3-3ζ interacting proteins in 
the hippocampus we used an immunoprecipita-
tion-pull down approach. Recombinant human 
His-tagged 14-3-3ζ was expressed and purified 
from E. coli clones from the hEx1 library 
(ImaGenes, Berlin, Germany) according to previ-
ous descriptions with modifications [24]. For 
purification, proteins were extracted in a lysis 
buffer, sonicated and centrifuged to remove any 
insoluble cellular debris. Supernatant was 
loaded onto a column, washed, and then bound 
protein eluted with buffer containing imidazole 
followed by desalting, and concentration, and 
fast performance liquid chromatography. Puri-
fied proteins were separated by SDS-PAGE and 
stained with Commassie Blue to verify the size 
of the purified proteins against the expected 
value. Protein concentrations were determined 
using the MicroBCA assay (Pierce, Rockford, IL) 
according to manufacturer’s specifications.  
 
Elution of 14-3-3ζ-interacting proteins using His-
14-3-3ζ 
 
C57BL/6 adult male mice (Harlan, U.K.) were 
euthanized and hippocampi were dissected, 
immediately frozen and stored at -70oC until 
use. Hippocampi were then homogenised in ice-
cold lysis buffer (50 mM Tris-HCL, pH 8.0, 250 
mM NaCl, 10 mM imidazole, 0.5 % NP-40, pro-
tease and phosphatase inhibitor cocktails). Af-
ter 30 min, the lysate was centrifuged for 10 
min at 8000 x g to remove unbroken cells. The 
resultant supernatant was collected and pre-
cleared with 100 μl cobalt beads for 2 h. At the 
same time, 40 μg of His-tagged 14-3-3ζ was 
incubated with 100 μl of cobalt resin in 1 ml 
lysis buffer for 2 h, after which it was centri-
fuged and the resin washed with PBS. The co-
balt resin now bound with His-tagged protein 
was incubated with the precleared supernatant 
overnight. As a negative control supernatant 
was incubated with cobalt resin alone. The 
beads were then washed with lysis buffer with-
out NP-40 four to five times before eluting the 
14-3-3 complexes with 500 μl of 250 mM imi-
dazole. The eluate was precipitated with TCA, 
separated on 12 % SDS PAGE gels and stained 
with colloidal Coomassie. 
 
Mass spectrometry 
 
Gels were sliced into 10 bands for each lane. 
The bands were reduced, alkylated with io-
doacetamide, and in-gel digested with trypsin 
(Promega). The samples were subjected to LC-
MS/MS analysis as follows. Peptides were sepa-
rated on a 75 μm inner diameter x 15cm col-
umn (C18 Pepmap 100, 3um, Dionex) at a flow 
rate of 200 nl/min delivered by an Ultimate 
3000 nano-LC system (Dionex, U.K.) with the 
following solvent scheme: solvent A, 0.08 % 
formic acid; solvent B, 90 % acetonitrile in 0.08 
% formic acid. Samples were loaded in solvent 
A, and peptides were eluted by 7 % solvent B for 
3 min followed by a linear gradient to 50 % sol-
vent B for 45 min and holding the column at 95 
% solvent B for 5 min before re-equilibrating the 
system for 10 min using 7 % solvent B. Up to 3 
peptide precursor ions were subjected to data-
dependent acquisition of tandem mass spectra 
using an ion trap mass spectrometer (HCT Ultra, 
14-3-3 zeta proteomics  
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Bruker). Tandem mass spectra were converted 
into peak lists using DataAnalysis (Bruker Dal-
tonics) and searched against mouse ENSEMBL 
v.46 (http://aug2007.archive.ensembl.org/
index.html) using X!Tandem (version 
2007.07.01.2) [25] and the following parame-
ters: parent ion mass tolerance: ± 300 ppm, 
fragment ion tolerance: 0.3 Da, tryptic cleavage 
specificity allowing for one missed cleavage site, 
fixed modification: carbamidomethyl, variable 
modifications: carbamidomethylated cysteines 
and N-terminal protein acetylation, refinement 
search parameters were set to the following 
additional modifications: deamidation of Asn 
and Gln, phosphorylation of Ser, Thr and Tyr, 
oxidation and dioxidation of Met and Trp, methy-
lation of Cys, Asp, Asn, Glu, His, Lys and Arg, 
dehydration of Ser and Thr, carbamidomethyla-
tion of Lys, His, Asp and Glu, missed carbami-
domethylation of Cys. All search results had a 
false positive rate of less than 1.5% [26]. All 
proteins that were identified with only one pep-
tide were validated manually by comparing 
them against higher scoring entries gpmdb 
(gpmdb.thegpm.org). 
 
Subcellular fractionation 
 
Subcellular fractionation was undertaken using 
the sucrose technique as previously described 
with modifications [27]. Briefly, hippocampus (n 
= 3) from C57BL/6 mice was homogenized in 1 
x M-SHE buffer (210 mM Mannitol, 70 mM Su-
crose, 10 mM HEPES-KOH pH 7.4, 1 mM EDTA, 
1 mM EGTA and a protease inhibitor cocktail) 
and then centrifuged twice at 1200 x g for 10 
min. The pellet that remained contained the 
nucleus and unlysed cells and was stored on ice 
for further purification later. The post-nuclear 
supernatant was then centrifuged twice at 
10,000 x g for 15 min and the resulting mito-
chondrial pellet was resuspended in a sucrose 
buffer (395 mM Sucrose, 0.1 mM EGTA, 10 mM 
HEPES-KOH pH 7.4) and purified through a per-
coll bilayer in gradient buffer (1.28 M Sucrose, 
0.4 mM EGTA, 40 mM HEPES-KOH, pH 7.4) by 
centrifugation at 41,000 x g for 30 min. The 
crude cytosolic fraction was then centrifuged at 
100,000 x g for 1 h to separate the microsomal 
and cytosolic fractions. The nuclear pellet was 
rehomogenised in 1 ml M-SHE buffer and centri-
fuged at 1000 x g for 10 min until a pellet bi-
layer was obtained, the supernatant was dis-
carded and the opaque layer of the pellet was 
retained and resuspended in 1 ml TSE buffer 
with 1 % NP-40. This step was repeated two 
more times until a monolayer pellet was ob-
tained which was then suspended in 40 μl of 
lysis buffer. Protein quantity per fraction was 
determined by BCA assay. Fraction quality was 
determined by immunoblotting with antibodies 
against markers for the cytoplasm (Bad, #9292, 
Cell Signaling Technology), mitochondria (Porin, 
ab34726, Abcam), nucleus (Lamin A/C, #2032, 
Cell Signaling Technology) and microsomes 
(protein disulfide isomerise (PDI), sc20132, 
Santa Cruz Biotechnology). Twenty micrograms 
of protein was then transferred to nitrocellulose 
membrane (Biorad), probed with antibodies 
against 14-3-3ζ (sc1019, Santa Cruz Biotech-
nology) and visualised using HRP-conjugated 
secondary antibody (Millipore) and visualised 
using a FujiFilm Las4000 system by chemilumi-
nescence. 
 
Gene ontology 
 
Gene ontology (GO) was undertaken for the 
identified proteins by uploading to the Database 
for Annotation, Visualization and Integrated Dis-
covery (http://david.abcc.ncifcrf.gov/) and cate-
gorized according to biological process, molecu-
lar function and cellular component, as de-
scribed [28]. 
 
Results 
 
Subcellular localization of 14-3-3ζ in the mouse 
hippocampus 
 
Although previous work reported the presence 
of 14-3-3ζ in the endoplasmic reticulum-
enriched microsomal fraction in the mouse [20], 
this work used organotypic cultures. To deter-
mine where 14-3-3ζ localizes in the adult 
mouse brain we analyzed the nuclear, mito-
chondria, cytoplasm and microsomal fractions 
prepared from hippocampus extracted from 
adult C57BL/6 mice. Western blotting deter-
mined that each fraction was enriched for es-
tablished markers and devoid of significant 
cross-contamination (Figure 1A). Thus, the Bcl-2 
family protein Bad was exclusively in the cyto-
plasm, Porin was only in the mitochondrial frac-
tion, Lamin A/C only in the nucleus, and PDI 
was found in the microsomal fraction (Figure 
1A). Western blot analysis determined 14-3-3ζ 
to be present in each fraction, being particularly 
abundant in the cytoplasm and the microsomes, 
while being present at somewhat lower levels in 
14-3-3 zeta proteomics  
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the nucleus and mitochondria (Figure 1B). 
 
Isolation and identification of 14-3-3ζ-binding 
proteins  
 
Successful MS analysis of 14-3-3ζ target pro-
teins in the hippocampus depended on the ex-
pression and purification of the His-tagged re-
combinant human 14-3-3ζ which was expressed 
and isolated from E. Coli and used in the subse-
quent pull-down experiments. Purity of the His-
tagged protein was confirmed by 1D electropho-
resis and Coomassie staining (Figure 2A) and 
was estimated to be 99% purified. Western blot 
analysis verified the specificity of the protein as 
being 14-3-3ζ (Figure 2B). Faint bands detected 
using antibodies against other isoforms likely 
result from known cross-reactivity [6].  
 
To identify 14-3-3ζ-interacting proteins in the 
mouse hippocampus, the His-tagged 14-3-3ζ 
was incubated with precleared protein lysate 
from mouse hippocampus. Proteins bound to 
14-3-3ζ were eluted, processed and identified 
by mass spectrometry. The experiment was per-
formed in duplicate. In the first study a total of 
111 proteins passed the criteria for detection 
(see Methods) and in the second experiment, 
110 proteins were identified (data not shown). 
The common proteins among the two lists (29 in 
total) are shown in Table 1. Included in this list 
were 10 proteins that have previously been vali-
dated as 14-3-3 binding proteins. Many of these 
proteins were identified with high confidence 
(Table 1). Three 14-3-3 isoforms were also de-
tected; β, θ and γ, which were most likely in het-
ero-dimeric formation with the zeta isoform. The 
remaining 16 proteins identified are potentially 
novel 14-3-3ζ binding proteins (Table 1). 
 
Gene ontology analysis of 14-3-3ζ binding 
proteins 
 
To explore the biological functions of the 14-3-3 
binding proteins we used gene ontology soft-
ware and analyzed biological process, molecular 
function and cellular component (Figure 3). 
Among biological processes, were synaptic 
transmission and protein transport, as well as 
protein kinase and neuronal migration (Figure 
3A). For molecular function, binding was the 
Figure 1. Subcellular location of 14-3-3ζ in the mouse 
hippocampus. (A) Western blots validate the fraction 
purity using markers specific for each subcellular 
compartment; Lamin A/C for nuclear, Bad for cyto-
plasm, Porin for mitochondria and PDI for the micro-
somal fraction. (B) Representative western blot show-
ing 14-3-3ζ in each subcellular compartment. α-
Tubulin is included as a guide to protein loading. 
Figure 2. Characterization of recombinant His-tagged 
14-3-3ζ used for proteomics. (A) Coomassie stained 
gel of the purified protein. (B) Western blot analysis 
of the purified protein. The strongest band was seen 
when the protein was immunoblotted using antibod-
ies against the zeta isoform of 14-3-3. 
14-3-3 zeta proteomics  
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most prominent category (lipid, ATP, ion and 
nucleotide) (Figure 3B). Finally, among cellular 
component the cytoplasm and plasma mem-
brane, nucleus and synapse, and both Golgi and 
endoplasmic reticulum featured (Figure 3C).  
 
Discussion 
 
The present studied used recombinant His-
tagged 14-3-3ζ to identify potentially novel 14-3
-3ζ binding proteins in the mouse hippocampus. 
Using a proteomic LC-MS/MS approach we 
identified a number of previously known 14-3-3 
binding proteins, including other 14-3-3 iso-
forms, and a series of potentially new 14-3-3ζ 
binding proteins. We also included an analysis 
of the subcellular distribution of 14-3-3ζ in the 
mouse hippocampus which revealed the pres-
ence of 14-3-3ζ within the endoplasmic reticu-
lum-containing microsomal fraction, supporting 
previous work. These studies identify additional 
14-3-3ζ interacting proteins which may be im-
portant in normal brain function or in disease. 
 
Defining the 14-3-3ζ interactome is an impor-
tant goal if we are to fully understand the myr-
iad functions and processes regulated by this 
member of the 14-3-3 family. Significant efforts 
Table 1. Common 14-3-3ζ-interacting proteins 
14-3-3 zeta proteomics  
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have been expended toward full characteriza-
tion of the 14-3-3 interactome using proteomics
-based approaches [9] and 
the present work extends 
findings on other isoforms 
[12, 13]. Here, we used 
recombinant human His-
tagged 14-3-3ζ to elute 14-
3-3 binding proteins from 
mouse hippocampus. Thus, 
our approach is most simi-
lar to that used in HeLa 
cells to characterize the 14
-3-3ζ interactome during 
interphase and mitosis 
[29]. The choice of 14-3-3ζ 
as bait is particular apt 
given the implication of this 
isoform in neurodegenera-
tive, neurologic and neuro-
psychiatric diseases [7, 17-
19] and also because 14-3-
3ζ may function to oppose 
endoplasmic reticulum 
stress [20], an important 
trigger of apoptosis [30]. 
Altogether we identified 29 
proteins, a number very 
similar to that reported for 
the 14-3-3ζ interatome in 
HEK293 cells [12]. This 
included a number of 
known 14-3-3ζ-interacting 
proteins, including three 
other 14-3-3 isoforms. In 
addition to other isoforms 
of 14-3-3, we identified 
proteins previously been 
identified as interacting 
with 14-3-3 including Kine-
sin light chain 2 [31], 
Adam22 [32] and Cofilin 
[33]. Taken together, these 
results provide confidence 
that the approach we used 
was suitable for identifying 
14-3-3ζ-interacting pro-
teins. 
 
Our study also identified 16 
potentially novel 14-3-3ζ 
interacting proteins in the 
mouse hippocampus. This 
included Kif5c, a member 
of the kinesin family in-
volved in cytoskeletal functions, members of 
which have previously been shown to interact 
Figure 3. Gene ontology analysis of 14-3-3ζ binding proteins. The DAVID bioinfor-
matics tool was used to categorize the 14-3-3ζ proteomics list according to GO 
processes (A) Biological process; (B) Molecular function and (C) Cellular compo-
nent.  
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with 14-3-3ζ [29, 34]. We also detected Nsf, a 
vesicle-fusing ATPase [35]. Although an interac-
tion with 14-3-3ζ has not been reported previ-
ously, this protein functions in synaptic trans-
mission and 14-3-3 isoforms are known to regu-
late several proteins with ATPase activity [9]. 
Two ribosomal proteins were eluted by 14-3-3ζ 
in our study which is consistent with findings 
reported for the HeLa cell 14-3-3ζ interactome 
[29]. Rps27a is involved in ubiquitin metabo-
lism and although no previous study has linked 
this gene to 14-3-3ζ, 14-3-3ζ is involved in ubiq-
uitin-regulation of proteins [36] and 14-3-3 pro-
teins are themselves targets for ubiquitin-
dependent regulation [37]. Similarly, Trim pro-
teins are known to target 14-3-3 for ubiquitin-
mediated degradation [38] and here we identi-
fied Trim32 as a potentially novel 14-3-3ζ-
interacting protein. Another detected protein 
was Arhgef7 which has not previously been re-
ported to bind 14-3-3, although members of the 
Rho guanine exchange factor family have been 
shown to be regulated by 14-3-3 [39]. Nckipsd 
(SPIN90) is another protein associated with 
neuronal function, expressed in dendritic spines 
where it promotes spine density [40]. Relatively 
little is known about the function of Slc25a3 in 
the brain but it has been reported to control the 
release of pro-apoptotic protein from mitochon-
dria [41]. We detected 14-3-3ζ in the mitochon-
drial fraction of mouse hippocampus and our 
study may therefore have identified a novel 
apoptosis-regulatory protein with which 14-3-3 
can interact. Given the association between 
changes to 14-3-3ζ and human temporal lobe 
epilepsy it is notable that among the novel pro-
teins was Lgi1, a gene deleted in certain epilep-
sies [42]. Slc25a12 was also detected, a gene 
whose absence results in global hypomyelina-
tion and seizures [43]. A further potential link to 
epilepsy comes from the identification of 14-3-
3ζ as a binding protein for a common anti-
epileptic drug [44]. 
 
Our gene ontology analysis extended insights 
beyond the proteomic work. As would be ex-
pected, prominent in the analysis were proteins 
associated with the cytoplasm and synapse. 
This is consistent with the original work identify-
ing these as important sites of 14-3-3 localiza-
tion [6] and work since that has linked 14-3-3 
functions to neurotransmission [5]. Proteins 
known to reside within the Golgi apparatus and 
the endoplasmic reticulum also featured in the 
cellular component category in agreement with 
the established roles of 14-3-3 in trafficking 
proteins and in endoplasmic reticulum stress 
[45]. Predictably, binding dominated the cate-
gory of biological and molecular function. How-
ever, other categories were also found, includ-
ing ubiquitin and kinase function, which have 
been emphasized in 14-3-3 proteomic and 
other work previously [29, 46, 47]. Also, among 
molecular function were neuronal migration, a 
process previously linked to 14-3-3ζ [48, 49]. 
Notably, Cheah et al recently reported that mice 
lacking 14-3-3ζ show aberrant development of 
the hippocampus with migratory defects of py-
ramidal cells and granular neurons as well as 
abnormal synaptic input on pyramidal neurons 
[19].  
 
The present study also included a subcellular 
analysis of 14-3-3ζ in the mouse hippocampus. 
Previous work on this isoform has been under-
taken using rat brain [6] and human material 
[7]. 14-3-3ζ like other members of the family is 
thought to be most abundant in the cytosol, but 
the protein is also present in the synaptic com-
partment [6], in mitochondria and in the micro-
somal fraction which contains the endoplasmic 
reticulum [7, 20]. Our data are consistent with 
these reports and we found 14-3-3ζ in the cyto-
plasm, mitochondria and microsomes. In addi-
tion, we report 14-3-3ζ in the nuclear compart-
ment of the mouse hippocampus. This localiza-
tion is consistent with roles for 14-3-3 proteins 
in regulating trafficking and function of nuclear 
proteins [50, 51]. 
 
Some caveats should be considered in the pre-
sent study. The list of proteins is probably a sig-
nificant underestimate of the 14-3-3ζ interac-
tome in the mouse hippocampus. Foremost is 
the limitation of sensitivity and detection, par-
ticularly taking into account the small size and 
the resulting small amounts of material to be 
analyzed in this study. We cannot assume that 
proteins eluted by 14-3-3ζ represent direct bind-
ing to 14-3-3ζ rather than extraction as part of a 
multi-protein complex or their presence as un-
specific binders, although the latter was signifi-
cantly mitigated in the design of our experiment 
through the use of precleared lysates. Beyond 
this, we selected only those proteins detected in 
both experiments, which increases confidence 
in the proteins we identified being bone fide 14-
3-3ζ-interacting proteins in the mouse hippo-
campus but we have probably missed others. 
Another consideration is our use of human re-
14-3-3 zeta proteomics  
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combinant 14-3-3ζ as bait to elute 14-3-3ζ bind-
ing proteins. Presumably, only those proteins 
freely available for binding and under the condi-
tions in our pull-down study could be identified. 
Many proteins already complexed to endoge-
nous 14-3-3ζ would be missed. Further insights 
may be obtained if experiments used subcellu-
lar fractions rather than whole cell lysates, given 
the variable presence of 14-3-3ζ between com-
partments in the mouse hippocampus. Also, 
because the lysates would contain both glial 
and neuron populations, we do not know in 
which cell population these interactions occur. 
Finally, future studies must include individual 
validation experiments to confirm the specificity 
of the interactions and validate these proteins 
as bona fide targets of 14-3-3ζ.  
 
In conclusion, this study shows the presence of 
14-3-3ζ in four subcellular compartments in the 
mouse hippocampus. We characterized the 14-
3-3ζ interactome in this tissue and present a 
novel list of potential interacting proteins which 
were previously unknown. Together, our studies 
expand our knowledge about the potential tar-
gets of 14-3-3ζ which may contribute to our un-
derstanding of the physiological and disease-
related roles of this protein in the brain.  
 
Acknowledgements 
 
This study was funded by Science Foundation 
Ireland award 04/IN3/B466 and 08/IN1/
B1875 and by the Programme for Research in 
Third Level Institutions (PRTLI cycle 3). The au-
thors would like to thank Jorin Pang and Ina 
Woods for technical support. 
 
Address correspondence to: Dr. David C. Henshall, 
Department of Physiology & Medical Physics, Royal 
College of Surgeons in Ireland, 123 St. Stephen’s 
Green, Dublin 2, IRELAND Tel: +353 1 402 8629; 
Fax: +353 1 402 2447; E-mail: dhenshall@rcsi.ie 
 
References 
 
[1] Fu H, Subramanian RR and Masters SC. 14-3-3 
proteins: structure, function, and regulation. 
Annu Rev Pharmacol Toxicol 2000; 40: 617-
647. 
[2] Tzivion G, Shen YH and Zhu J. 14-3-3 proteins; 
bringing new definitions to scaffolding. Onco-
gene 2001; 20: 6331-6338. 
[3] Aitken A. 14-3-3 proteins: a historic overview. 
Semin Cancer Biol 2006; 16: 162-172. 
[4] Kleppe R, Martinez A, Doskeland SO and 
Haavik J. The 14-3-3 proteins in regulation of 
cellular metabolism. Semin Cell Dev Biol 2011; 
22: 713-719. 
[5] Berg D, Holzmann C and Riess O. 14-3-3 pro-
teins in the nervous system. Nat Rev Neurosci 
2003; 4: 752-762. 
[6] Martin H, Rostas J, Patel Y and Aitken A. Sub-
cellular localization of 14-3-3 isoforms in rat 
brain using specific antibodies. J Neurochem 
1994; 63: 2259-2265. 
[7] Schindler CK, Heverin M and Henshall DC. Iso-
form- and subcellular fraction-specific differ-
ences in hippocampal 14-3-3 levels following 
experimentally evoked seizures and in human 
temporal lobe epilepsy. J Neurochem 2006; 99: 
561-569. 
[8] Wang J, Lou HY, Pedersen CJ, Smith AD and 
Perez RG. 14-3-3 zeta contributes to tyrosine 
hydroxylase activity in MN9D cells: Localization 
of dopamine regulatory protein sto mitochon-
dria. J Biol Chem 2009; 284: 14011-14019. 
[9] Bridges D and Moorhead GB. 14-3-3 proteins: a 
number of functions for a numbered protein. 
Sci STKE 2005; 2005: re10. 
[10] Yaffe MB, Rittinger K, Volinia S, Caron PR, Ait-
ken A, Leffers H, Gamblin SJ, Smerdon SJ and 
Cantley LC. The structural basis for 14-3-3 : 
phosphopeptide binding specificity. Cell 1997; 
91: 961-971. 
[11] Pozuelo Rubio M, Geraghty KM, Wong BH, 
Wood NT, Campbell DG, Morrice N and Mackin-
tosh C. 14-3-3-affinity purification of over 200 
human phosphoproteins reveals new links to 
regulation of cellular metabolism, proliferation 
and trafficking. Biochem J 2004; 379: 395-
408. 
[12] Jin J, Smith FD, Stark C, Wells CD, Fawcett JP, 
Kulkarni S, Metalnikov P, O'Donnell P, Taylor P, 
Taylor L, Zougman A, Woodgett JR, Langeberg 
LK, Scott JD and Pawson T. Proteomic, func-
tional, and domain-based analysis of in vivo 14-
3-3 binding proteins involved in cytoskeletal 
regulation and cellular organization. Curr Biol 
2004; 14: 1436-1450. 
[13] Benzinger A, Muster N, Koch HB, Yates JR and 
Hermeking H. Targeted proteomic analysis of 
14-3-3 sigma, a p53 effector commonly si-
lenced in cancer. Mol Cell Proteomics 2005; 4: 
785-795. 
[14] Chang IF, Curran A, Woolsey R, Quilici D, Cush-
man JC, Mittler R, Harmon A and Harper JF. 
Proteomic profiling of tandem affinity purified 
14-3-3 protein complexes in Arabidopsis 
thaliana. Proteomics 2009; 9: 2967-2985. 
[15] Satoh J, Nanri Y and Yamamura T. Rapid identi-
fication of 14-3-3-binding proteins by protein 
microarray analysis. J Neurosci Meth 2006; 
152: 278-288. 
[16] Freeman AK and Morrison DK. 14-3-3 Proteins: 
diverse functions in cell proliferation and can-
cer progression. Semin Cell Dev Biol 2011; 22: 
681-687. 
[17] Hashiguchi M, Sobue K and Paudel HK. 14-3-3 
14-3-3 zeta proteomics  
 
 
82                                                                                  Int J Physiol Pathophysiol Pharmacol 2012;4(2):74-83 
zeta is an effector of tau protein phosphoryla-
tion. J Biol Chem 2000; 275: 25247-25254. 
[18] Umahara T, Uchihara T, Yagishita S, Nakamura 
A, Tsuchiya K and Iwamoto T. Intranuclear im-
munolocalization of 14-3-3 protein isoforms in 
brains with spinocerebellar ataxia type 1. Neu-
rosci Lett 2007; 414: 130-135. 
[19] Cheah PS, Ramshaw HS, Thomas PQ, Toyo-Oka 
K, Xu X, Martin S, Coyle P, Guthridge MA, Stom-
ski F, van den Buuse M, Wynshaw-Boris A, Lo-
pez AF and Schwarz QP. Neurodevelopmental 
and neuropsychiatric behaviour defects arise 
from 14-3-3 zeta deficiency. Molecular Psychia-
try 2012; 17: 451-466. 
[20] Murphy N, Bonner HP, Ward MW, Murphy BM, 
Prehn JHM and Henshall DC. Depletion of 14-3-
3 zeta elicits endoplasmic reticulum stress and 
cell death, and increases vulnerability to 
kainate-induced injury in mouse hippocampal 
cultures. J Neurochem 2008; 106: 978-988. 
[21] Kim YS, Choi MY, Kim YH, Jeon BT, Lee DH, Roh 
GS, Kang SS, Kim HJ, Cho GJ and Choi WS. 
Protein kinase Cdelta is associated with 14-3-3 
phosphorylation in seizure-induced neuronal 
death. Epilepsy Res 2010; 92: 30-40. 
[22] Murphy N, Yamamoto A and Henshall DC. De-
tection of 14-3-3 zeta in cerebrospinal fluid 
following experimentally evoked seizures. Bio-
markers 2008; 13: 377-384. 
[23] Schoonheim PJ, Veiga H, Pereira DD, Friso G, 
van Wijk KJ and de Boer AH. A comprehensive 
analysis of the 14-3-3 interactome in barley 
leaves using a complementary proteomics and 
two-hybrid approach. Plant Physiology 2007; 
143: 670-683. 
[24] Kijanka G, Ipcho S, Baars S, Chen H, Hadley K, 
Beveridge A, Gould E and Murphy D. Rapid 
characterization of binding specificity and cross
-reactivity of antibodies using recombinant hu-
man protein arrays. J Immunol Methods 2009; 
340: 132-137. 
[25] Craig R and Beavis RC. TANDEM: matching 
proteins with tandem mass spectra. Bioinfor-
matics 2004; 20: 1466-1467. 
[26] Gupta N, Bandeira N, Keich U and Pevzner PA. 
Target-decoy approach and false discovery rate: 
when things may go wrong. J Am Soc Mass 
Spectrom 2011; 22: 1111-1120. 
[27] Schindler CK, Shinoda S, Simon RP and Hen-
shall DC. Subcellular distribution of Bcl-2 family 
proteins and 14-3-3 within the hippocampus 
during seizure-induced neuronal death in the 
rat. Neurosci Lett 2004; 356: 163-166. 
[28] McKiernan RC, Jimenez-Mateos EM, Bray I, 
Engel T, Brennan GP, Sano T, Michalak Z, 
Moran C, Delanty N, Farrell M, O'Brien D, Meller 
R, Simon RP, Stallings RL and Henshall DC. 
Reduced mature microRNA levels in associa-
tion with Dicer loss in human temporal lobe 
epilepsy with hippocampal sclerosis. PLoS One 
2012; 7: e35921. 
[29] Meek SE, Lane WS and Piwnica-Worms H. Com-
prehensive proteomic analysis of interphase 
and mitotic 14-3-3-binding proteins. J Biol 
Chem 2004; 279: 32046-32054. 
[30] Hetz C. The unfolded protein response: control-
ling cell fate decisions under ER stress and 
beyond. Nat Rev Mol Cell Biol 2012; 13: 89-
102. 
[31] Ichimura T, Wakamiya-Tsuruta A, Itagaki C, 
Taoka M, Hayano T, Natsume T and Isobe T. 
Phosphorylation-dependent interaction of kine-
sin light chain 2 and the 14-3-3 protein. Bio-
chemistry 2002; 41: 5566-5572. 
[32] Godde NJ, D'Abaco GM, Paradiso L and Novak 
U. Efficient ADAM22 surface expression is me-
diated by phosphorylation-dependent interac-
tion with 14-3-3 protein family members. J Cell 
Sci 2006; 119: 3296-3305. 
[33] Birkenfeld J, Betz H and Roth D. Identification 
of cofilin and LIM-domain-containing protein 
kinase 1 as novel interaction partners of 14-3-3 
zeta. Biochem J 2003; 369: 45-54. 
[34] Dorner C, Ullrich A, Haring HU and Lammers R. 
The kinesin-like motor protein KIF1C occurs in 
intact cells as a dimer and associates with pro-
teins of the 14-3-3 family. J Biol Chem 1999; 
274: 33654-33660. 
[35] Hanson PI, Otto H, Barton N and Jahn R. The N-
ethylmaleimide-sensitive fusion protein and 
alpha-SNAP induce a conformational change in 
syntaxin. J Biol Chem 1995; 270: 16955-
16961. 
[36] Mizuno E, Kitamura N and Komada M. 14-3-3-
dependent inhibition of the deubiquitinating 
activity of UBPY and its cancellation in the M 
phase. Exp Cell Res 2007; 313: 3624-3634. 
[37] Choi HH, Gully C, Su CH, Velazquez-Torres G, 
Chou PC, Tseng C, Zhao R, Phan L, Shaiken T, 
Chen J, Yeung SC and Lee MH. COP9 signalo-
some subunit 6 stabilizes COP1, which func-
tions as an E3 ubiquitin ligase for 14-3-3sigma. 
Oncogene 2011; 30: 4791-4801. 
[38] Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, 
Muramatsu M, Ouchi Y and Inoue S. Efp targets 
14-3-3 sigma for proteolysis and promotes 
breast tumour growth. Nature 2002; 417: 871-
875. 
[39] Diviani D, Abuin L, Cotecchia S and Pansier L. 
Anchoring of both PKA and 14-3-3 inhibits the 
Rho-GEF activity of the AKAP-Lbc signaling com-
plex. EMBO J 2004; 23: 2811-2820. 
[40] Lee S, Lee K, Hwang S, Kim SH, Song WK, Park 
ZY and Chang S. SPIN90/WISH interacts with 
PSD-95 and regulates dendritic spinogenesis 
via an N-WASP-independent mechanism. EMBO 
J 2006; 25: 4983-4995. 
[41] Alcala S, Klee M, Fernandez J, Fleischer A and 
Pimentel-Muinos FX. A high-throughput screen-
ing for mammalian cell death effectors identi-
fies the mitochondrial phosphate carrier as a 
regulator of cytochrome c release. Oncogene 
2008; 27: 44-54. 
[42] Gu W, Brodtkorb E and Steinlein OK. LGI1 is 
14-3-3 zeta proteomics  
 
 
83                                                                                  Int J Physiol Pathophysiol Pharmacol 2012;4(2):74-83 
mutated in familial temporal lobe epilepsy char-
acterized by aphasic seizures. Ann Neurol 
2002; 52: 364-367. 
[43] Wibom R, Lasorsa FM, Tohonen V, Barbaro M, 
Sterky FH, Kucinski T, Naess K, Jonsson M, 
Pierri CL, Palmieri F and Wedell A. AGC1 defi-
ciency associated with global cerebral hypo-
myelination. N Engl J Med 2009; 361: 489-
495. 
[44] Park KD, Kim D, Reamtong O, Eyers C, Gaskell 
SJ, Liu R and Kohn H. Identification of a laco-
samide binding protein using an affinity bait 
and chemical reporter strategy: 14-3-3 zeta. J 
Am Chem Soc 2011; 133: 11320-11330. 
[45] Shikano S, Coblitz B, Wu M and Li M. 14-3-3 
proteins: regulation of endoplasmic reticulum 
localization and surface expression of mem-
brane proteins. Trends Cell Biol 2006; 16: 370-
375. 
[46] Tzivion G, Luo Z and Avruch J. A dimeric 14-3-3 
protein is an essential cofactor for Raf kinase 
activity. Nature 1998; 394: 88-92. 
[47] Dai JG and Murakami K. Constitutively and 
autonomously active protein kinase C associ-
ated with 14-3-3 zeta in the rodent brain. J 
Neurochem 2003; 84: 23-34. 
[48] Toyo-oka K, Shionoya A, Gambello MJ, Cardoso 
C, Leventer R, Ward HL, Ayala R, Tsai LH, 
Dobyns W, Ledbetter D, Hirotsune S and Wyn-
shaw-Boris A. 14-3-3 epsilon is important for 
neuronal migration by binding to NUDEL: a mo-
lecular explanation for Miller-Dieker syndrome. 
Nat Gen 2003; 34: 274-285. 
[49] Tenney JR, Hopkin RJ and Schapiro MB. Dele-
tion of 14-3-3 epsilon and CRK: A Clinical Syn-
drome With Macrocephaly, Developmental De-
lay, and Generalized Epilepsy. J Child Neurol 
2011; 26: 223-227. 
[50] Grozinger CM and Schreiber SL. Regulation of 
histone deacetylase 4 and 5 and transcrip-
tional activity by 14-3-3-dependent cellular 
localization. Proc Natl Acad Sci USA 2000; 97: 
7835-7840. 
[51] Rajendran P, Delage B, Dashwood WM, Yu TW, 
Wuth B, Williams DE, Ho E and Dashwood RH. 
Histone deacetylase turnover and recovery in 
sulforaphane-treated colon cancer cells: com-
peting actions of 14-3-3 and Pin1 in HDAC3/
SMRT corepressor complex dissociation/
reassembly. Mol Cancer 2011; 10: 68. 
 
